vs
艾伯维（ARGX）与Cellectis S.A.（CLLS）财务数据对比。点击上方公司名可切换其他公司
艾伯维的季度营收约是Cellectis S.A.的260.3倍（$2.5B vs $9.5M）。艾伯维净利率更高（35.5% vs -265.9%，领先301.4%）。Cellectis S.A.同比增速更快（375.0% vs 83.2%）。艾伯维自由现金流更多（$322.4M vs $27.6M）
艾伯维是总部位于美国伊利诺伊州北芝加哥的制药企业，研发生产的药物覆盖多种疾病治疗领域，可满足多元临床需求，致力于为全球不同病症的患者提供可靠的治疗方案选择。
Cellectis S.A.是一家法国生物制药公司，专注于开发用于癌症免疫治疗的基因编辑嵌合抗原受体T细胞技术，目前在巴黎、纽约以及北卡罗来纳州罗利均设有办公机构，在肿瘤免疫基因编辑疗法领域拥有多年研发积累。
ARGX vs CLLS — 直观对比
营收规模更大
ARGX
是对方的260.3倍
$9.5M
营收增速更快
CLLS
高出291.8%
83.2%
净利率更高
ARGX
高出301.4%
-265.9%
自由现金流更多
ARGX
多$294.8M
$27.6M
损益表 — Q4 2025 vs Q2 2024
| 指标 | | |
|---|---|---|
| 营收 | $2.5B | $9.5M |
| 净利润 | $877.2M | $-25.3M |
| 毛利率 | 89.5% | — |
| 营业利润率 | 28.9% | -181.1% |
| 净利率 | 35.5% | -265.9% |
| 营收同比 | 83.2% | 375.0% |
| 净利润同比 | 1.3% | -51.9% |
| 每股收益（稀释后） | $13.25 | $-0.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ARGXCLLS
| Q4 25 | $2.5B | — | ||
| Q2 25 | $1.8B | — | ||
| Q4 24 | $1.4B | — | ||
| Q2 24 | $901.9M | $9.5M | ||
| Q3 23 | — | $1.6M | ||
| Q2 23 | $510.9M | $2.0M | ||
| Q2 22 | $116.7M | $2.7M |
净利润ARGXCLLS
| Q4 25 | $877.2M | — | ||
| Q2 25 | $414.8M | — | ||
| Q4 24 | $865.6M | — | ||
| Q2 24 | $-32.5M | $-25.3M | ||
| Q3 23 | — | $-17.5M | ||
| Q2 23 | $-123.2M | $-16.6M | ||
| Q2 22 | $-435.9M | $-19.5M |
毛利率ARGXCLLS
| Q4 25 | 89.5% | — | ||
| Q2 25 | 89.2% | — | ||
| Q4 24 | 90.2% | — | ||
| Q2 24 | 89.4% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | 91.7% | 97.3% | ||
| Q2 22 | 94.5% | 87.9% |
营业利润率ARGXCLLS
| Q4 25 | 28.9% | — | ||
| Q2 25 | 19.2% | — | ||
| Q4 24 | 8.7% | — | ||
| Q2 24 | -15.4% | -181.1% | ||
| Q3 23 | — | -1258.1% | ||
| Q2 23 | -40.3% | -1180.5% | ||
| Q2 22 | -340.5% | -1003.0% |
净利率ARGXCLLS
| Q4 25 | 35.5% | — | ||
| Q2 25 | 23.4% | — | ||
| Q4 24 | 64.1% | — | ||
| Q2 24 | -3.6% | -265.9% | ||
| Q3 23 | — | -1064.1% | ||
| Q2 23 | -24.1% | -831.6% | ||
| Q2 22 | -373.7% | -714.4% |
每股收益（稀释后）ARGXCLLS
| Q4 25 | $13.25 | — | ||
| Q2 25 | $6.32 | — | ||
| Q4 24 | $13.33 | — | ||
| Q2 24 | $-0.55 | $-0.28 | ||
| Q3 23 | — | $-0.31 | ||
| Q2 23 | $-2.21 | $-0.20 | ||
| Q2 22 | $-8.16 | $-0.42 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.5B | $149.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $7.3B | $148.6M |
| 总资产 | $8.7B | $407.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ARGXCLLS
| Q4 25 | $3.5B | — | ||
| Q2 25 | $2.1B | — | ||
| Q4 24 | $1.5B | — | ||
| Q2 24 | $1.4B | $149.0M | ||
| Q3 23 | — | — | ||
| Q2 23 | $1.1B | $84.4M | ||
| Q2 22 | $1.4B | $129.4M |
总债务ARGXCLLS
| Q4 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | $11.0M | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
股东权益ARGXCLLS
| Q4 25 | $7.3B | — | ||
| Q2 25 | $6.1B | — | ||
| Q4 24 | $5.5B | — | ||
| Q2 24 | $4.3B | $148.6M | ||
| Q3 23 | — | $76.1M | ||
| Q2 23 | $2.9B | $96.6M | ||
| Q2 22 | $3.0B | $180.5M |
总资产ARGXCLLS
| Q4 25 | $8.7B | — | ||
| Q2 25 | $7.2B | — | ||
| Q4 24 | $6.2B | — | ||
| Q2 24 | $4.8B | $407.1M | ||
| Q3 23 | — | $209.7M | ||
| Q2 23 | $3.2B | $227.7M | ||
| Q2 22 | $3.2B | $320.9M |
负债/权益比ARGXCLLS
| Q4 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | 0.00× | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $323.3M | $28.9M |
| 自由现金流经营现金流 - 资本支出 | $322.4M | $27.6M |
| 自由现金流率自由现金流/营收 | 13.0% | 290.5% |
| 资本支出强度资本支出/营收 | 0.0% | 13.2% |
| 现金转化率经营现金流/净利润 | 0.37× | — |
| 过去12个月自由现金流最近4个季度 | $594.5M | — |
8季度趋势，按日历期对齐
经营现金流ARGXCLLS
| Q4 25 | $323.3M | — | ||
| Q2 25 | $361.8M | — | ||
| Q4 24 | $41.9M | — | ||
| Q2 24 | $-124.7M | $28.9M | ||
| Q3 23 | — | — | ||
| Q2 23 | $-285.4M | $-47.4M | ||
| Q2 22 | $-494.5M | $-60.2M |
自由现金流ARGXCLLS
| Q4 25 | $322.4M | — | ||
| Q2 25 | $356.6M | — | ||
| Q4 24 | $40.9M | — | ||
| Q2 24 | $-125.5M | $27.6M | ||
| Q3 23 | — | — | ||
| Q2 23 | $-285.9M | $-47.9M | ||
| Q2 22 | $-494.7M | $-61.7M |
自由现金流率ARGXCLLS
| Q4 25 | 13.0% | — | ||
| Q2 25 | 20.1% | — | ||
| Q4 24 | 3.0% | — | ||
| Q2 24 | -13.9% | 290.5% | ||
| Q3 23 | — | — | ||
| Q2 23 | -56.0% | -2391.4% | ||
| Q2 22 | -424.0% | -2266.7% |
资本支出强度ARGXCLLS
| Q4 25 | 0.0% | — | ||
| Q2 25 | 0.3% | — | ||
| Q4 24 | 0.1% | — | ||
| Q2 24 | 0.1% | 13.2% | ||
| Q3 23 | — | — | ||
| Q2 23 | 0.1% | 24.1% | ||
| Q2 22 | 0.2% | 56.6% |
现金转化率ARGXCLLS
| Q4 25 | 0.37× | — | ||
| Q2 25 | 0.87× | — | ||
| Q4 24 | 0.05× | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
